Navigation Links
SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
Date:5/12/2011

SeraCare's revenues over the next three to four years."

SeraCare reported revenue of $11.0 million for the quarter ended March 31, 2011 compared to $12.9 million for the same quarter of the prior year, reflecting a 14 percent decrease. Gross margins decreased to 40 percent for the quarter compared to 43 percent for the same quarter of the prior year. SeraCare earned net income of $1.4 million and earnings per share on a basic and diluted basis of $0.07 for the quarter ended March 31, 2011 compared to net income of $2.1 million and earnings per share on a basic and diluted basis of $0.11 during the same period in fiscal 2010.  

Recent Corporate Highlights:

  • Achieved eighth consecutive quarter of profitability during the second quarter of fiscal 2011
  • Appointed a highly experienced Vice President of Sales and Marketing, Sean O'Connor. Mr. O'Connor, previously Director of Strategic Accounts at Ortho Clinical Diagnostics, a Johnson & Johnson company, brings more than 15 years of sales management experience in growing product revenues and creating new channel opportunities to SeraCare
  • Significantly expanded efforts to optimize the sales organization to drive growth, with a continued focus on diagnostics and pharmaceutical product sales in both North America and Europe
  • Introduced two new products in the second quarter of fiscal 2011
  • Increased cash balance to $16.9 million as of March 31, 2011
  • Generated $0.9 million in cash from operations during the quarter ended March 31, 2011, marking our ninth consecutive quarter of positive cash from operations
  • Added two new members to our Board of Directors, Kevin Hrusovsky and Joseph Nemmers—both with extensive experience in the life sciences industry

  • Conference Call Information:The conference call will be webcast live over the Internet and can be accessed by logging on to the "Investor Center, Events" section of the SeraCar
    '/>"/>

    SOURCE SeraCare Life Sciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. SeraCare Announces the Election of Joseph Nemmers and Kevin Hrusovsky to the Board of Directors
    2. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
    3. SeraCare Reports First Quarter Fiscal Year 2011 Results
    4. SeraCare Life Sciences to Report First Quarter 2011 Financial Results on February 11, 2011
    5. SeraCare Life Sciences Secures $20 Million Credit Facilities
    6. PharmAthene Reports First Quarter 2011 Financial and Operating Results
    7. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
    8. BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results
    9. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
    10. GenVec Reports First Quarter 2011 Financial Results
    11. American Oriental Bioengineering Reports First Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/25/2014)... Lawrence Livermore scientists Charles Westbrook and William ... " The World's Most Influential Scientific Minds ." , ... who were identified by analyzing citation data over the ... highest-impact work (2002-2012 and 2012-2013). The two were selected ... . , "This recognition is a great honor for ...
    (Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
    (Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
    (Date:7/24/2014)... and synthetic processes prefer to settle into equilibriuma ... is within the realm of non-equilibrium conditions where ... in energy and phases, such as temperature fluctuations, ... humans to regulate their body temperature, airplanes to ... activity. , But even though these conditions ...
    Breaking Biology Technology:Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2
    ... SAN DIEGO, Oct. 4 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the 28th Annual Scientific Meeting of ... the San Diego Convention Center, October 8-12, 2010.Sunday, October ...
    ... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... special dividend payment of $0.50 per share to all stockholders ... record date. As previously announced, the conversion ... 15, 2012 was adjusted to 140.571 shares of common stock ...
    ... 1 Biotech posted its strongest monthly and quarterly performance ... September rally for equities in more than 70 years. The ... and 13 percent in the third quarter. The Dow Jones ... appreciation during what historically has been a bad month for ...
    Cached Biology Technology:Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society 2Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear 2Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear 3Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear 4
    (Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
    (Date:7/24/2014)... NEW YORK, NY (July 24, 2014) Scientists ... Research Institute are one step closer to creating ... from a patient,s own cells. , For ... stem (iPS) cells lines from skin samples of ... they developed an accelerated protocol to induce these ...
    (Date:7/24/2014)... /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative technology ... emergency room wait times by an average of 92 ... according to a recent study published in the Academic ... the suite to access data from incoming patients, implanted ... "Using Geneva,s technology platform we have been able to ...
    Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
    ... to develop and evaluate new tools to control the ... five year, 12 million project involving sixteen partners in ... Framework programme. Because malaria is transmitted by mosquitoes, ... Wide scale use of insecticides on bednets and ...
    ... has long been used as a crop fertilizer, but the ... in manure is ever present. The ratio of nitrogen to ... needs of most crops. Therefore, crops tend to be overloaded ... but the excess phosphorus from the process can damage the ...
    ... "The rapid translation of biologically-based laboratory discoveries into daily ... trip back from the clinic to the laboratory, to ... behavior. It is imperative for basic researchers to understand ... the knowledge and skills to integrate and use new ...
    Cached Biology News:€12 million ($16.9 million) project to develop new tools for malaria control 2
    UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
    ...
    ... suitable for use with RNA. ... with 0.1% diethylpyrocarbonate (DEPC) and ... DEPC.DNase/RNase-Free Distilled WaterDistilled Water is ... molecular biology applications. It is ...
    IHC detection kit for BrdU in cells and tissues...
    Biology Products: